Deoxycytidine kinase inhibition: Rewiring tumor nucleotide metabolism for therapeutic gain

Read full text Summarise with VIRAT
Authors: Peter M. Clark, Curtis B. Thompson, Kenneth A. Schultz
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Deoxycytidine kinase (dCK) is the rate-limiting enzyme of the deoxyribonucleoside salvage pathway, phosphorylating deoxyadenosine, deoxycytidine, and deoxyguanosine to sustain intracellular deoxyribonucleoside triphosphate (dNTP) pools. Replication stress and DNA damage enhance dCK activity, creating tumor dependence on salvage-mediated dNTP supply for DNA repair and survival. Genetic contexts such as BRCA2 loss and mutant p53 further heighten this vulnerability. This review synthesizes mechanistic evidence linking dCK to stress-adaptive nucleotide metabolism, summarizes progress in small-molecule dCK inhibitor development, and highlights dCK inhibitor TRE-515 as the first clinically tested agent, alongside plasma nucleoside profiling and PET imaging as translational pharmacodynamic biomarkers.

Fields of Study & Subjects

Biochemical and Molecular Research DNA Repair Mechanisms Cancer Hypoxia and Metabolism

Publication details

Journal / source
Figshare
Publication date
27 March 2026
Language
EN
Document type
Dataset